Even Without a Lexicography One Term May Have More Than One Meaning
| May 29, 2013
Title: Even Without a Lexicography One Term May Have More Than One Meaning
Author Name: Bernadette K. McGann
Case Name: Aventis Pharmaceuticals Inc. v. Amino Chemicals Ltd.
Key words: Claim Construction, Intrinsic Evidence, Prosecution History
Decision Date: May 20, 2013
CAFC Panel and opinion author: Newman, Bryson and Reyna. Opinion by Reyna. Dissenting opinion by Bryson
Summary
The claim in dispute recites a process of preparing a piperidine derivative compound that included providing a substantially pure regioisomer of a specific formula. The District Court construed the meaning of “substantially pure” in relation to an intermediate compound to mean 98% purity, which is the same meaning as “substantially pure” when in relation to the piperidine derivative end product. The CAFC reversed the “one construction throughout the patent” rule, adopted by the District Court.
Tags: claim construction > intrinsic evidence > prosecution history
CAFC Reverses Trial Court’s Indefiniteness Ruling
| May 9, 2013
Biosig Instruments v. Nautilus
April 26, 2013
Panel: Wallach, Schall and Newman. Opinion by Wallach. Concurrence by Schall.
Summary
The Court of Appeals for the Federal Circuit rarely finds patent claims to be so indefinite that the they are invalid under 35 U.S.C. § 112, ¶ 2. This historical proclivity was on display last in the CAFC’s decision in Biosig Instruments V. Nautilus. There, the Court reversed a summary judgment of invalidity for indefiniteness, concluding that the claim was “amenable to construction” and not ‘insolubly ambiguous.”
Tags: claim construction > indefiniteness
Clear and Unmistakeable Evidence of a Disclaimer Found in Response to Enablement Rejection
| April 24, 2013
Biogen Idec, Inc., et al. v. GlaxoSmithKline LLC, et al.
April 16, 2013
Panel: Dyk, Plager, Reyna. Opinion by Reyna. Dissent by Plager.
Summary
During prosecution of the patent, applicants responded to the examiner’s enablement rejection, wherein they failed to challenge the examiner’s understanding of the crucial terms, and limited their invention to what the examiner believed their specification enabled. The CAFC affirmed the district court’s narrow claim interpretation of the term “anti-CD20 antibody” based on prosecution history disclaimer.
実施可能要件を満たしていないとして発せられた拒絶通知に対して、出願人は、審査官の理解に対して反論することなく、明細書により実施可能であると審査官が判断したものに発明を限定するような主張を行った。よって、「anti-CD20 antibody」という用語について、狭いクレーム解釈を容認した地裁の判断は誤りでなかったとCAFCは判示した。
Tags: claim construction > disclaimer > estoppel > prosecution disclaimer > prosecution history disclaimer > prosecution history estoppel
Divided Claim Construction Leads to Reversal of Jury Verdict Against Alleged Infringer
| April 17, 2013
Saffran v. Johnson & Johnson
April 4, 2013
Panel: Lourie, Moore, and O’Malley. Opinion by Lourie. Concurrence Opinions by Moore and O’Malley.
Summary
The Federal Circuit reversed a $482 million jury verdict against Cordis, a member of the Johnson & Johnson family. The reversal came as a result of the Federal Circuit’s significant narrowing of the district court’s construction of two key claim limitations. One claim term was narrowed because the Federal Circuit found that the patentee’s arguments made during prosecution of the asserted patent, for the purpose of distinguishing over cited prior art, amounted to prosecution disclaimer. Meanwhile, a structure identified in the specification by the patentee as the corresponding structure to a means-plus-function limitation was disregarded as such, because the specification failed to link the identified structure to the recited function with sufficient specificity.
Tags: claim construction > infringement > means-plus-function > prosecution argument > prosecution disclaimer > prosecution history estoppel
Prior Art Reference Must Disclose Arrangement of Elements, Not Merely Each Discrete Element
| March 20, 2013
SynQor, Inc., v. Artesyn Technologies, Inc., et al.
March 13, 2013
Panel: Rader, Lourie and Daniel (Chief District Judge). Opinion by Rader.
Summary
SynQor sued Artesyn Technologies, Inc., and eight other power converter manufactures (Defendants) for infringement of five of SynQor’s U.S. Patents in the United States District Court (“DC”) for the Eastern District of Texas. The DC granted partial summary judgment of infringement of against the Defendants. The DC denied Defendants’ motion for judgment as a matter of law (JMOL) or a new trial after the jury found all asserted claims infringed, not invalid, and awarded lost-profits of $95 million. On appeal, the CAFC affirmed the DC based on a review of the record evidence.
Tags: anticipation > claim construction > ThomasBrown
Entirely reasonable? “Black box” claim interpretation by split Federal Circuit panel leaves us in the dark
| February 13, 2013
Harris Corp. v. Fed Ex Corp. (non-precedential)
January 17, 2013
Panel: Lourie, Clevenger, and Wallach. Opinion by Clevenger. Dissent by Wallach
Summary:
Over a dissent, the Federal Circuit panel makes a strict interpretation of “antecedent basis,” which results in a reversal of the District Court’s claim interpretation, and a remand to re-evaluate the infringement issue.
Harris’s patents cover methods and systems for using spread spectrum radio signals to send flight data from a plane’s “black box” to an airport receiver at the end of the flight. The invention includes steps of generating, accumulating and storing flight data in the plane during the flight, followed by a step of “transmitting the accumulated, stored generated aircraft data” once at the airport.
At the District Court, a jury found that Fed Ex willfully infringed Harris’s patents by using a “design-around” system that transmits all flight data except an optional 5-minute segment.
On appeal, the Federal Circuit panel majority holds that Harris patent claims are limited to the transmission of “all data generated during the flight,” not just any data subset representative of the flight. The panel’s view is that the narrower interpretation is “entirely reasonable” since the transmitting step refers to the generating step.
In contrast, the dissent sees the claim language as open, so that it would be “counterintuitive” to require that all the generated data must be transmitted.
Tags: antecedent basis > claim construction > claim interpretation
Claim Construction and Expert Testimony in Pharmaceutical Patent Litigation
| January 31, 2013
Allergan, Inc. v. Barr Laboratories, Inc., Teva Pharmaceutical USA, Inc., and Teva Pharmaceutical Industries Ltd. and Sandoz Inc.
January 28, 2013
Panel: Rader, Bryson and Wallach. Opinion by Bryson.
Summary
Barr Lab. and Sandoz Inc. etc. (collectively Defendants) filed a Abbreviated New Drug Application (ANDA), listing the patented product in Allergan’s ‘819 patent. Allergan filed an infringement suit against the Defendants. The district court ruled for Allergan, and the Defendants brought it to appeal.
One major point of dispute was about one moiety in the claimed compounds described in claim 5 of patent ‘819 as representable by –N(R4)2. The Defendants asserted that the two R4 moieties must be construed as identical. The district court and the CAFC both found for Allergan in holding that the R4 units did not need to be identical.
Another point of dispute was about the requirement for courts’ independent inquiry into “obviousness” type of patent invalidity case. The CAFC affirmed the district court’s decision that the expert testimony may be a required part of patent invalidity cases based on obviousness, and that independent review of a case involving complex technology, in absence of expert witness, is not required.
Barr Labs和Sandoz公司（以下统称被告）向联邦食品药品管理局提出简化新药申请（ANDA）中将Allergan公司的819专利所保护的专利药品列为仿制药。 Allergan公司对被告提起侵权诉讼。联邦地区法院裁定Allergan胜诉，被告遂到联邦巡回法庭提出上诉。
争议要点之一是，在专利819的权利要求5，对要求受保护药物的描述包括该化合物含有基团 “–N（R 4）2”。被告声称，这两个R4基团应该理解为相同基团。区法院和联邦巡回上诉法院都认同Allergan的理解，认定对R4基团定义应基于该专利文件中的具体描述，所以两个R4基团不一定相同。
另一个争议点是专利无效请求的案件中法院是否有义务进行独立调查。联邦巡回上诉法院肯定了地区法院的判决，即专家证词可能是专利无效案件的证据的必要组成部分，而当专利无效案件涉及复杂的技术时，在专利无效请求人未提供专家证人的情况下，法庭不需要独立调查案件即可直接判定专利无效请求人应证据不足败诉。
Tags: ANDA > claim construction > expert witness > markush group
Dealing with Different Embodiments of the Specification
| December 26, 2012
Sandisk Corp. v. Kingston Tech. Co., Inc.
October 9, 2012
Panel: Prost, Reyna and Wallach. Opinion by Prost. Dissent by Reyna.
Summary
The claim construction of the term “relative time” caused the issue whether one of two different embodiments of the specification should be excluded from the scope of literal infringement. The district court excluded the second embodiment, focusing on the claim term “time.” CAFC disagrees, emphasizing the significance of the claim term “relative.” Judge Reyna dissents.
明細書が2つの実施例を含んでいる場合に、クレームの文言が両方の実施例をカバーしているのか、それとも片方の実施例は除外されるべきかが問題となった事件である。この問題は、クレームに記載された「相対的な時間」(relative time)の文言解釈をどのように行うかによって判断が分かれた。地裁ならびにdissent(反対意見)は、クレームの「時間」(time)を厳格に解釈して第2実施例を除外すべきと判断した。CAFCは、クレームの「相対的」(relative)に重きを置き、第2実施例を除外すべきでないと判断した。「両方の実施例がクレームでカバーされる」という一言が明細書に含まれていれば、この問題は回避できたと思われる。
Read More/続きを読む
Tags: claim construction > exclusion of embodiment > multiple embodiments
CAFC does not find means-plus-function in a “height adjustment mechanism”
| November 7, 2012
Flo Heathcare Solutions v. Kappos
October 23, 2012
Panel: Newman, Plager, and Wallach. Opinion by Wallach.
PROCEDURAL SUMMARY
The patentee sued the defendant for infringement. The defendant then requested inter partes reexamination of the patent. The trial judge stayed the infringement action, pending completion of the reexamination. The patent reexamination examiner and the Patent Office Board rejected the claims as being anticipated by the prior art. On appeal, the CAFC disagreed with the PTO Board’s claim construction; but even under the CAFC’s claim construction, it found that the claims were anticipated and therefore affirmed the PTO’s rejection of the claims
Tags: claim construction > means > means-plus-function > reexamination
Apple is bit at CAFC: The Court reversed and remanded a preliminary injunction obtained at the District Court against Samsung’s Galaxy Nexus Smartphone
| October 17, 2012
Apple Inc. v. Samsung Electronics, Ltd. et al.
Decided: October 11, 2012
Panel: Prost, Moore, and Reyna. Opinion by Prost.
Summary
The CAFC reversed the District Court’s finding that there was irreparable harm to Apple by allowing sales of the Galaxy Nexus. The CAFC held that there was an insufficient causal nexus between the claimed invention and the sales of the product. The Court also addressed Apple’s likelihood of success to interject claim construction.
Tags: claim construction > galaxy nexus > injunction > irreparable harm > likelihood of success > nexus > preliminary injunction > smartphone
